Brokerages Set Hikma Pharmaceuticals PLC (LON:HIK) Target Price at GBX 2,250

Hikma Pharmaceuticals PLC (LON:HIK) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is GBX 2,325 ($30.57).

A number of analysts recently commented on HIK shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 2,750 ($36.16) price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday, June 18th. Berenberg Bank raised shares of Hikma Pharmaceuticals to a “buy” rating and boosted their price objective for the company from GBX 2,100 ($27.61) to GBX 2,400 ($31.56) in a research report on Monday, September 2nd.

Hikma Pharmaceuticals Stock Performance

LON HIK opened at GBX 1,956 ($25.72) on Friday. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.48. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,711 ($22.50) and a fifty-two week high of GBX 2,165 ($28.47). The business has a fifty day moving average of GBX 1,923.37 and a 200-day moving average of GBX 1,921.04. The stock has a market cap of £4.34 billion, a price-to-earnings ratio of 3,009.23, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41.

Hikma Pharmaceuticals Cuts Dividend

The business also recently disclosed a dividend, which will be paid on Friday, September 20th. Stockholders of record on Thursday, August 15th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a dividend yield of 1.37%. Hikma Pharmaceuticals’s payout ratio is currently 9,538.46%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.